Is CareDx, Inc. (CDNA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.1% / 30% | 28.3% / 30% | 7.0% / 30% | 3.52% / 5% | ✓ HALAL |
| DJIM | 3.1% / 33% | 28.3% / 33% | 7.0% / 33% | 3.52% / 5% | ✓ HALAL |
| MSCI | 5.8% / 33% | 53.1% / 33% | 13.2% / 33% | 3.52% / 5% | ✗ NOT HALAL |
| S&P | 3.1% / 33% | 28.3% / 33% | 7.0% / 33% | 3.52% / 5% | ✓ HALAL |
| FTSE | 5.8% / 33% | 53.1% / 33% | 13.2% / 50% | 3.52% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 67.6% | |
| Operating Margin | -3.5% | |
| Net Margin | -5.6% | |
| Return on Equity (ROE) | -6.3% | |
| Return on Assets (ROA) | -3.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $42M |
| Free Cash Flow | $35M |
| Total Debt | $26M |
| Debt-to-Equity | 8.6 |
| Current Ratio | 2.9 |
| Total Assets | $413M |
Price & Trading
| Last Close | $17.47 |
| 50-Day MA | $18.97 |
| 200-Day MA | $16.77 |
| Avg Volume | 669K |
| Beta | 2.6 |
|
52-Week Range
$10.96
| |
About CareDx, Inc. (CDNA)
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Purification Calculator
As a halal stock with 3.52% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CareDx, Inc. (CDNA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CareDx, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CareDx, Inc.'s debt ratio?
CareDx, Inc.'s debt ratio is 3.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.8%.
Does CareDx, Inc. require dividend purification?
Yes, CareDx, Inc. has an impermissible income ratio of 3.52%, which means 3.52% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are CareDx, Inc.'s key financial metrics?
CareDx, Inc. has a market capitalization of $863M, and revenue of $380M. The company maintains a gross margin of 67.6% and a net margin of -5.6%. Return on equity stands at -6.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.